Atlas Trials

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Clinical trial NCT04697069 · TERMINATED

Trial details

NCT number
NCT04697069
Sponsor
Vanda Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acneiform Eruptions
Start date
2021-05-04
Primary completion
2021-12-13
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.